Innovative Strategies by Inventiva at September Investor Events
Inventiva's Upcoming Investor Conferences
Inventiva, a clinical-stage biopharmaceutical company, is excited to announce its participation in several key investor events this September. The company specializes in developing innovative oral therapies aimed at treating metabolic dysfunction-associated steatohepatitis (MASH). These conferences present an excellent opportunity for the company to share its latest advancements and engage with investors interested in the biopharmaceutical landscape.
Featured Conferences in September
H.C. Wainwright 27th Annual Global Investment Conference
On September 9, 2025, Inventiva will participate in the H.C. Wainwright 27th Annual Global Investment Conference. The company's leadership will take part in a fireside chat at 3:00 PM EDT, which offers investors insights into Inventiva’s strategic vision and pipeline developments.
Lyon Pôle Bourse Forum
Following this, on September 23, Inventiva will showcase its projects at the 8th Edition of the Lyon Pôle Bourse Forum. This event is pivotal for those engaged in investment and innovation in the health sector, making it an ideal platform for Inventiva to connect with key stakeholders.
KBC Life Sciences Conference
On September 25, 2025, Inventiva will also be present at the KBC Life Sciences Conference in Brussels, Belgium. The scheduled presentation at 5:00 AM EDT will focus on the company’s ongoing clinical trials and the potential impact of its flagship compound lanifibranor in addressing MASH.
Stifel 2025 Virtual Cardiometabolic Forum
Finally, on September 30, Inventiva will participate in the Stifel 2025 Virtual Cardiometabolic Forum. During this arena, the company's representatives will discuss innovations in cardiometabolic health and how their treatments are evolving to meet patient needs.
Understanding Inventiva's Mission and Goals
Inventiva is dedicated to developing effective solutions for conditions often overlooked in standard healthcare practices. The company’s lead candidate, lanifibranor, is a novel pan-PPAR agonist currently undergoing pivotal Phase 3 trials. These trials are crucial for evaluating its efficacy and safety profile to help patients suffering from MASH—a condition that can lead to serious liver complications.
Inventiva stands out by focusing on unmet medical needs and harnessing innovative research approaches. By actively participating in these investor events, the company aims to keep investors informed and engaged with its mission to advance public health through transformative therapies.
Company Overview
As a public entity listed on Euronext Paris and the Nasdaq Global Market (ticker: IVA), Inventiva is positioned at the forefront of biopharmaceutical innovations. The firm continues to attract attention from investors eager to support groundbreaking solutions in healthcare.
For further information or inquiries, please reach out to:
Pascaline Clerc
EVP, Strategy and Corporate Affairs
Email: media@inventivapharma.com
Phone: +1 202 499 8937
ICR Healthcare Contacts:
**Alexis Feinberg**
Media Relations
Email: inventivapr@icrhealthcare.com
Phone: +1 203 939 2225
**Patricia L. Bank**
Investor Relations
Email: patti.bank@icrhealthcare.com
Phone: +1 415 513 1284
Frequently Asked Questions
1. What is the focus of Inventiva's upcoming presentations?
Inventiva's presentations will primarily focus on their clinical trials and the innovative therapies they are developing for MASH.
2. When and where will Inventiva be presenting?
Inventiva will be presenting at multiple events throughout September, including both in-person and virtual conferences.
3. Who are the key contacts at Inventiva?
Pascaline Clerc, EVP of Strategy and Corporate Affairs, is a primary contact along with the communications team at ICR Healthcare.
4. What is lanifibranor?
Lanifibranor is a novel therapy being developed by Inventiva for the treatment of metabolic dysfunction-associated steatohepatitis.
5. How can I get more information about Inventiva?
Additional information can be found on their official website and by contacting their media relations team via email.
About The Author
Contact Addison Perry privately here. Or send an email with ATTN: Addison Perry as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.